[ad_1]
An Israeli startup of biotechnology claims to have found the definitive cure for cancer. According to Accelerated Evolution Biotechnology (AEBi) the treatment is suitable for all types of cancer, generates few side effects and has pbaded rodent tests. "We believe that one year from now, we will be able to offer a comprehensive cure for cancer," said Dan Aridor, member of the startup 's board of directors.
In an interview with the Jerusalem Post Dr. Ilan Morad, AEBi's CEO explained that his team was trying to understand why other cancer treatments were failing. "Our results are consistent and reproducible," says Aridor. "Our results are consistent and reproducible," says Aridor. The first tests, in vitro, were successful. Then with rodents, still a success. Human carcinogenic cells, inserted into animals, were inhibited; healthy rats did not have any side effects of treatment. The next step is to launch human clinical trials, which should take place in the next few years.
MuTaTo: treatment
Named MuTaTo (abbreviation for multi-target or multi-target toxin). ), the treatment is similar to badtail against AIDS, according to Morad. "Before, we gave AIDS patients several drugs, administered one by one," he says. "During treatment, the virus mutated and the disease came back in. It's only when patients started using the badtail at one point that the disease was controlled."
In the same spirit, MuTaTo acts at the same time on all the cancer cells and in each of their parts. This prevents them from mutating during treatment and becoming resistant to the drug. Unlike AIDS, however, cancer cells die and the patient does not remain a carrier of the disease. Therefore, you do not need to take medication for the rest of your life.
Although it is general – and effectively attacks all cells that can generate cancer mutations – the treatment promises to be limited to the diseased part. In other words, it will not work on healthy cells, which for example reduces common side effects in traditional chemotherapy
. In addition, the treatment developed by AEBi is individualized. The idea of scientists is that the patient performs a series of tests and develops a personalized medicine for his type of cancer. This ensures the effectiveness against the cells of a specific cancer and avoids the side effects generated by a "universal" remedy
. MuTaT is the product of a growing trend in biotechnology. Last year, researchers won the Nobel Prize for generating laboratory-specific proteins (mainly antibodies) from viruses that infect bacteria. The process performed by AEBi is the same, with the difference that instead of producing antibodies, the proteins are peptides. According to Morad, they are "cheaper, smaller and simpler to produce"
Cancer in the New Economy
Cancer is the second leading cause of death in the world, behind cardiovascular disease. In the world of startups and technological innovations, several initiatives are being taken to reduce the damage caused by the disease.
A new start for health successfully tests a new treatment for cancer
A health startup successfully tests a new treatment against cancer
[ad_2]Source link
